US2008189798A1PendingUtilityA1
Non-mammalian transgenic animal model for cellular proliferative diseases
Est. expiryAug 4, 2019(expired)· nominal 20-yr term from priority
Inventors:Patrick Fogarty
A01K 67/68C12N 15/8509C07K 14/82A01K 2217/05A01K 2267/0331A01K 2227/706A01K 67/0271
59
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Non-mammalian, transgenic animals, e.g. flies, that exhibit neoplastic phenotypes, i.e. spontaneously produce metastatic tumors, are provided. Also provided are methods of using the subject transgenic non-mammalian animals to identify compounds having activity with respect to cellular proliferative, and particularly neoplastic, diseases. Finally, kits for screening compounds for anti-neoplastic activity are provided.
Claims
exact text as granted — not AI-modified1 . A non-mammalian transgenic animal, wherein said transgenic animal spontaneously develops metastatic tumors and comprises a v-myb transgene.
2 . The transgenic non-mammalian animal according to claim 1 , wherein said transgenic non-mammalian animal is an invertebrate.
3 . The transgenic non-mammalian animal according to claim 2 , wherein said invertebrate is an insect.
4 . A transgenic fly that spontaneously develops metastatic tumors and comprises a v-myb transgene.
5 . The transgenic fly according to claim 4 , wherein said fly is a member of the family Drosophilidae.
6 . The transgenic fly according to claim 5 , wherein said fly is a Drosophila melanogaster.
7 . The transgenic fly according to claim 4 , wherein said v-myb transgene is expressed in the amnioserosa and peripheral nervous system.
8 . A transgenic Drosophila melanogaster that spontaneously develops metastatic tumors and comprises a v-myb transgene.
9 . A method of screening a compound for activity with respect to cellular proliferative diseases, said method comprising:
administering said compound to a non-mammalian animal according to claim 1 ; and observing the effect of said compound on said animal.
10 . The method according to claim 9 , wherein said non-mammalian animal is a transgenic invertebrate.
11 . The method according to claim 10 , wherein said invertebrate is an insect.
12 . The method according to claim 11 , wherein said insect is a fly.
13 . The method according to claim 9 , wherein said compound is orally administered to said animal.
14 . A method of screening a compound for activity with respect to a neoplastic disease, said method comprising:
feeding said compound to a non-mammalian animal according to claim 1 ; and observing the effect of said compound on said animal.
15 . The method according to claim 14 , wherein said compound is present in a nutrient medium.
16 . A method of screening a plurality of compounds for activity with respect to cellular proliferative disease, said method comprising:
feeding said plurality of compounds to a plurality of non-mammalian animals according to claim 1 in a manner sufficient to ensure that each animal is fed only a single type compound from said plurality of compounds; and observing the effect of said compounds on said plurality of animals.
17 . The method according to claim 16 , wherein said compound is present in a nutrient medium. (nutrient medium includes water)
18 . A method of identifying whether a gene is capable of modulating a neoplastic disease condition, said method comprising:
mutating said gene in a non-mammalian animal according to claim 1 ; and determining whether said mutation modulates the phenotype of said non-mammalian animal model.
19 . The method according to claim 18 , wherein said modulating is enhancing.
20 . The method according to claim 18 , wherein said modulating is suppressing.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.